Ryan S Youland1, Paul D Brown, Caterina Giannini, Ian F Parney, Joon H Uhm, Nadia N Laack. 1. *College of Medicine Departments of ‡Pathology §Neurosurgery ∥Neurology ¶Radiation Oncology, Mayo Clinic, Rochester, MN †Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
OBJECTIVES: To determine prognostic factors and optimal timing of postoperative radiation therapy (RT) in adult low-grade gliomas. METHODS: Records from 554 adults diagnosed with nonpilocytic low-grade gliomas at Mayo Clinic between 1992 and 2011 were retrospectively reviewed. RESULTS: Median follow-up was 5.2 years. Histology revealed astrocytoma in 22%, oligoastrocytoma in 34%, and oligodendroglioma in 45%. Initial surgery achieved gross total resection in 31%, radical subtotal resection in 10%, subtotal resection (STR) in 21%, and biopsy only in 39%. Median overall survival (OS) and progression-free survival (PFS) were 11.4 and 4.1 years, respectively. On multivariate analysis, factors associated with lower OS included astrocytomas and use of postoperative RT. Adverse prognostic factors for PFS on multivariate analysis included tumor size, astrocytomas, STR/biopsy only and not receiving RT. Patients undergoing gross total resection/radical subtotal resection had the best OS and PFS. Comparing survival with the log-rank test demonstrated no association between RT and PFS (P=0.24), but RT was associated with lower OS (P<0.0001). In patients undergoing STR/biopsy only, RT was associated with improved PFS (P<0.0001) but lower OS (P=0.03). Postoperative RT was associated with adverse prognostic factors including age > 40 years, deep tumors, size≥5 cm, astrocytomas and STR/biopsy only. Patients delaying RT until recurrence experienced 10-year OS (71%) similar to patients never needing RT (74%; P=0.34). CONCLUSIONS: This study supports the association between aggressive surgical resection and better OS and PFS, and between postoperative RT and improved PFS in patients receiving STR/biopsy only. In addition, our findings suggest that delaying RT until progression is safe in patients who are eligible.
OBJECTIVES: To determine prognostic factors and optimal timing of postoperative radiation therapy (RT) in adult low-grade gliomas. METHODS: Records from 554 adults diagnosed with nonpilocytic low-grade gliomas at Mayo Clinic between 1992 and 2011 were retrospectively reviewed. RESULTS: Median follow-up was 5.2 years. Histology revealed astrocytoma in 22%, oligoastrocytoma in 34%, and oligodendroglioma in 45%. Initial surgery achieved gross total resection in 31%, radical subtotal resection in 10%, subtotal resection (STR) in 21%, and biopsy only in 39%. Median overall survival (OS) and progression-free survival (PFS) were 11.4 and 4.1 years, respectively. On multivariate analysis, factors associated with lower OS included astrocytomas and use of postoperative RT. Adverse prognostic factors for PFS on multivariate analysis included tumor size, astrocytomas, STR/biopsy only and not receiving RT. Patients undergoing gross total resection/radical subtotal resection had the best OS and PFS. Comparing survival with the log-rank test demonstrated no association between RT and PFS (P=0.24), but RT was associated with lower OS (P<0.0001). In patients undergoing STR/biopsy only, RT was associated with improved PFS (P<0.0001) but lower OS (P=0.03). Postoperative RT was associated with adverse prognostic factors including age > 40 years, deep tumors, size≥5 cm, astrocytomas and STR/biopsy only. Patients delaying RT until recurrence experienced 10-year OS (71%) similar to patients never needing RT (74%; P=0.34). CONCLUSIONS: This study supports the association between aggressive surgical resection and better OS and PFS, and between postoperative RT and improved PFS in patients receiving STR/biopsy only. In addition, our findings suggest that delaying RT until progression is safe in patients who are eligible.
Authors: Robert B Jenkins; Hilary Blair; Karla V Ballman; Caterina Giannini; Robert M Arusell; Mark Law; Heather Flynn; Sandra Passe; Sara Felten; Paul D Brown; Edward G Shaw; Jan C Buckner Journal: Cancer Res Date: 2006-10-15 Impact factor: 12.701
Authors: E G Shaw; C Daumas-Duport; B W Scheithauer; D T Gilbertson; J R O'Fallon; J D Earle; E R Laws; H Okazaki Journal: J Neurosurg Date: 1989-06 Impact factor: 5.115
Authors: M J van den Bent; D Afra; O de Witte; M Ben Hassel; S Schraub; K Hoang-Xuan; P-O Malmström; L Collette; M Piérart; R Mirimanoff; A B M F Karim Journal: Lancet Date: 2005 Sep 17-23 Impact factor: 79.321
Authors: Hamdy El-Hateer; Luis Souhami; David Roberge; Rolando Del Maestro; Richard Leblanc; Eman Eldebawy; Thierry Muanza; Denis Melançon; Petr Kavan; Marie-Christine Guiot Journal: J Neurosurg Date: 2009-08 Impact factor: 5.115
Authors: David A Schomas; Nadia N Issa Laack; Ravi D Rao; Fredric B Meyer; Edward G Shaw; Brian Patrick O'Neill; Caterina Giannini; Paul D Brown Journal: Neuro Oncol Date: 2008-11-18 Impact factor: 12.300
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Ryan S Youland; Cole R Kreofsky; David A Schomas; Paul D Brown; Jan C Buckner; Nadia N Laack Journal: J Neurooncol Date: 2017-08-23 Impact factor: 4.130
Authors: P D Delgado-López; E M Corrales-García; J Martino; E Lastra-Aras; M T Dueñas-Polo Journal: Clin Transl Oncol Date: 2017-03-02 Impact factor: 3.405
Authors: Ryan S Youland; David A Schomas; Paul D Brown; Chika Nwachukwu; Jan C Buckner; Caterina Giannini; Ian F Parney; Nadia N Laack Journal: Neuro Oncol Date: 2013-06-27 Impact factor: 12.300
Authors: Y Y Wang; T Zhang; S W Li; T Y Qian; X Fan; X X Peng; J Ma; L Wang; T Jiang Journal: AJNR Am J Neuroradiol Date: 2014-08-07 Impact factor: 3.825